Empagliflozin And Linagliptin

Introduction Overview

Generic Name

empagliflozin and linagliptin

Brand Name

Glyxambi

Dosage Form

Oral tablet

Drug Class

Antidiabetic combinations

Pharmacokinetics

Absorption:
Empagliflozin and linagliptin, the two active components of Glyxambi, are administered orally and show favorable pharmacokinetic profiles that support once-daily dosing. Empagliflozin is rapidly absorbed with peak plasma concentrations reached approximately 1.5 to 2 hours after administration under fasting conditions. Linagliptin absorption is also efficient, with peak concentrations occurring around 1.5 hours post-dose. Food does not significantly affect the overall bioavailability of either drug, allowing Glyxambi to be taken with or without food, which offers flexibility in patient adherence.

Distribution:
Empagliflozin exhibits a moderate plasma protein binding (~86.2%), primarily to albumin, which is reversible and concentration-independent. It distributes widely but does not extensively penetrate the central nervous system. Linagliptin demonstrates extensive tissue distribution, characterized by high binding to plasma proteins (>70%) including albumin and alpha-1 acid glycoprotein. It has a large volume of distribution (approximately 1110 liters), reflecting widespread distribution into tissues, which may contribute to its prolonged plasma half-life and sustained therapeutic effects.

Metabolism:
Empagliflozin undergoes minimal metabolism; approximately 10% of the dose is metabolized primarily via glucuronidation by UDP-glucuronosyltransferase enzymes UGT1A3, UGT1A8, and UGT2B7, producing inactive metabolites. This limited metabolism reduces the potential for significant drug-drug interactions through cytochrome P450 pathways. Linagliptin is primarily excreted unchanged, with only a minor fraction metabolized via CYP3A4, contributing to its minimal metabolic liability and a reduced risk of interactions, which is particularly beneficial in patients on polypharmacy.

Elimination:
Empagliflozin is eliminated mainly via renal excretion of parent drug and its inactive metabolites, with an elimination half-life of approximately 12 hours. It undergoes both renal and fecal excretion, with around 54% recovered in urine and 41% in feces. Linagliptin, in contrast, is mainly eliminated via enterohepatic circulation and fecal excretion (~80%), with less than 6% excreted renally, and exhibits a long terminal half-life (~12 hours) allowing for once-daily dosing. This elimination pattern in linagliptin is advantageous for patients with renal impairment. Combined, these pharmacokinetic characteristics enable Glyxambi to effectively control blood glucose with convenient daily dosing and a favorable safety profile.

Dosage Forms

Available Dosage Forms:
- Oral tablet formulations combining empagliflozin and linagliptin.
- Specific dosages include empagliflozin 10 mg with linagliptin 5 mg, and empagliflozin 25 mg with linagliptin 5 mg.

Dosages for Adults and Adolescents:
- The usual adult starting dose is empagliflozin 10 mg and linagliptin 5 mg once daily, taken orally in the morning.
- For patients tolerating the initial dose, the dosage of empagliflozin can be increased to 25 mg with linagliptin maintained at 5 mg once daily.
- The maximum recommended dose is empagliflozin 25 mg and linagliptin 5 mg daily.
- Glyxambi is not recommended for pediatric use in individuals under 18 years.

Specific Patient Populations:
- Glyxambi is contraindicated in patients with severe renal impairment or on dialysis, due to reduced efficacy and potential safety concerns.
- No dose adjustments are recommended based solely on age, but caution is advised in elderly patients (≥65 years) because of increased risk of dehydration or hypotension.
- Not approved for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
- Use with insulin or insulin secretagogues may require dose adjustments to reduce hypoglycemia risk.

Clinical guidelines emphasize empirical initiation at the lower dose with titration based on glycemic response and tolerability. The oral tablet's bioavailability and ease of administration support adherence and integration into comprehensive diabetes management plans.

Mechanism Of Action

Glyxambi is a fixed-dose combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, targeting type 2 diabetes mellitus via complementary mechanisms that synergistically improve glycemic control.

Empagliflozin selectively inhibits SGLT2 proteins located in the proximal renal tubules, reducing glucose reabsorption in the kidneys and promoting urinary glucose excretion. This insulin-independent mechanism helps lower plasma glucose levels by facilitating the removal of excess glucose through urine, leading to decreased blood glucose concentration, reduced glucotoxicity, and improved pancreatic beta-cell function. Furthermore, by inducing osmotic diuresis, empagliflozin also contributes to reduction in blood pressure and body weight, which are beneficial in diabetic patients with cardiovascular comorbidities.

Linagliptin inhibits the DPP-4 enzyme responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging incretin activity, linagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon release from alpha cells, resulting in improved postprandial and fasting blood glucose levels. Unlike other DPP-4 inhibitors, linagliptin undergoes minimal renal clearance, making it suitable for patients with varying degrees of renal function.

The combined action of empagliflozin and linagliptin addresses multiple pathophysiological defects of type 2 diabetes, including insulin resistance, decreased insulin secretion, and increased renal glucose reabsorption. Clinical trials demonstrate that this combination not only effectively improves glycemic parameters but also reduces cardiovascular risk and mortality in patients with established heart disease. The dual mechanism permits enhanced efficacy while minimizing the risk of hypoglycemia compared to traditional antidiabetic therapies. Comparative studies highlight that Glyxambi's combination therapy offers additive glycemic benefits and cardiovascular protection beyond those observed with monotherapies, establishing it as a valuable option in integrated diabetes care.

Pharmacological Actions

Selective inhibition of sodium-glucose cotransporter 2 (SGLT2) in renal proximal tubules leading to increased urinary glucose excretion.
Inhibition of dipeptidyl peptidase-4 (DPP-4) enzyme, enhancing endogenous incretin hormone levels.
Reduction of blood glucose levels by facilitating renal glucose elimination and augmenting glucose-dependent insulin secretion.
Improvement of pancreatic beta-cell function and decreased glucagon secretion, optimizing glycemic control.
Promotion of weight loss and modest blood pressure reduction due to osmotic diuresis induced by empagliflozin.
Cardioprotective effects demonstrated by reduction in risk of cardiovascular death, heart failure, and stroke in patients with type 2 diabetes and cardiovascular disease.
Minimal risk of hypoglycemia when used as monotherapy or in combination with non-insulin antidiabetic agents.
Provision of renal protective effects through lowering intraglomerular pressure and reducing hyperfiltration.
Synergistic glucose-lowering effect resulting from targeting different pathophysiologic mechanisms underlying type 2 diabetes.
Improvement in postprandial glucose control via enhancement of incretin hormone activity.
No significant CYP450-mediated drug interactions due to distinct metabolic pathways of empagliflozin and linagliptin.
Maintenance of efficacy in patients with mild to moderate renal impairment with appropriate dosing considerations.
Contribution to reduced albuminuria and potential delay of diabetic nephropathy progression.
Improved patient adherence through convenient once-daily oral dosing combination.

Therapeutic Or Clinical Uses

Adjunctive therapy with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Reduction of cardiovascular death risk in adults with type 2 diabetes and established cardiovascular disease.
Improvement of hemoglobin A1c (HbA1c) levels in patients inadequately controlled with monotherapy or dual therapy.
Reduction in fasting plasma glucose and postprandial glucose levels through complementary mechanisms.
Weight management assistance in overweight or obese patients with type 2 diabetes via empagliflozin-induced glucosuria.
Lowering risk of hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular comorbidities.
Potential renal protective effects by reducing intraglomerular pressure and albuminuria.
Alternative treatment option for patients intolerant to other antidiabetic agents due to favorable safety profile.
Management of type 2 diabetes in patients with moderate renal impairment where linagliptin component provides efficacy.
Part of combination therapy regimes aimed at delaying disease progression and minimizing diabetic complications.
Reduction of insulin requirements when used adjunctively with insulin or insulin secretagogues.
Improved patient compliance through fixed-dose combination reducing pill burden.
Use in patients at high risk for cardiovascular events who require both glycemic and cardiovascular risk management.
Potential use as step-up therapy for patients failing monotherapy with either empagliflozin or linagliptin.

Side Or Adverse Effects

Genital mycotic infections including candidiasis in males and females presenting as itching, burning, discharge, or erythema.
Urinary tract infections manifesting with dysuria, frequency, urgency, and sometimes pyuria.
Hypoglycemia especially when co-administered with insulin or insulin secretagogues such as sulfonylureas.
Dehydration-related symptoms including dizziness, hypotension, dry mouth, and increased thirst.
Gastrointestinal disturbances such as nausea, vomiting, and abdominal pain.
Serious but rare adverse effects like diabetic ketoacidosis even with normal or mildly elevated blood glucose levels.
Potential pancreatitis presenting as severe upper abdominal pain radiating to the back accompanied by nausea and vomiting.
Allergic reactions including rash, urticaria, angioedema, and in rare cases severe skin reactions.
Joint pain and musculoskeletal complaints reported in some patients.
Increased risk of fractures documented with prolonged use possibly related to altered calcium metabolism.
Electrolyte imbalances like increased serum potassium or phosphate abnormalities.
Headache, fatigue, and nasopharyngitis reported as common systemic symptoms.
Weight loss and increased urination frequency as pharmacodynamic effects.
Possible liver enzyme elevations though hepatotoxicity is rare.
Hypersensitivity reactions including anaphylaxis observed infrequently.

Precautions

Avoid use in patients with severe renal impairment, end-stage renal disease, or those on dialysis.
Monitor for signs and symptoms of ketoacidosis, especially during acute illness or surgery.
Exercise caution in elderly patients due to increased risk of volume depletion and hypotension.
Assess renal function regularly as worsening kidney function may reduce efficacy and increase adverse effects.
Caution with concurrent use of diuretics or antihypertensive agents due to additive risk of hypotension.
Patients with a history of genital infections should be monitored closely and counseled on hygiene.
Avoid use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Inform patients about potential for hypoglycemia and appropriate management strategies if used with insulin or secretagogues.
Advise patients to maintain adequate hydration, particularly during hot weather or exercise.
Avoid use during second and third trimesters of pregnancy due to potential fetal risk.
Do not use during breastfeeding as safety has not been established.
Discontinue therapy and seek immediate medical attention if symptoms suggestive of pancreatitis develop.
Consider risk-benefit in patients with a history of pancreatitis as safety in this population is not established.
Monitor for signs of serious allergic or skin reactions; discontinue if these occur.
Patients should inform healthcare providers of all medications to evaluate drug-drug interactions.

Warnings

Contraindicated in patients with severe kidney disease or those on dialysis due to lack of efficacy and increased risk.
Risk of life-threatening diabetic ketoacidosis despite normal blood glucose levels; patients must be monitored for symptoms.
Potential for serious genital infections including necrotizing fasciitis of the perineum (Fournier's gangrene).
Increased risk of hypoglycemia when combined with insulin or insulin secretagogues; dose adjustments may be required.
Avoid use in type 1 diabetes mellitus as may increase risk of diabetic ketoacidosis.
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.
Not recommended during pregnancy, especially in second and third trimesters, due to potential harm to the fetus.
Avoid use during breastfeeding as drug effects on infants are unknown and may be harmful.
Use with caution in elderly patients prone to dehydration and hypotension.
Possible risk of pancreatitis; patients should be informed to report severe abdominal pain immediately.
Monitor for severe or ongoing joint pain, which may necessitate discontinuation.
Discontinue Glyxambi if serious skin reactions or Stevens-Johnson syndrome occur.
May affect the accuracy of urine glucose tests due to increased urinary glucose excretion.
Risk of volume depletion-related adverse effects like dizziness and orthostatic hypotension, especially in patients on diuretics.
Avoid sudden discontinuation of therapy without medical advice as it may worsen glycemic control.

Contraindication

Known hypersensitivity or allergic reaction to empagliflozin, linagliptin, or any component of the formulation.
Severe renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73m2), end-stage renal disease, or patients on dialysis.
Current or history of diabetic ketoacidosis, including type 1 diabetes mellitus patients.
Pregnancy during the second and third trimesters due to potential fetal harm.
Known pancreatitis or history of severe pancreatic disease (use with caution as effects unclear).
Severe hepatic impairment as safety has not been established.
Patients with a history of serious hypersensitivity reactions to either empagliflozin or linagliptin.
Concurrent use with other SGLT2 inhibitors or DPP-4 inhibitors to avoid overlap and increased risk of adverse effects.
Children and adolescents under 18 years of age due to lack of safety and efficacy data.
Breastfeeding women until safety is confirmed.
Patients with conditions predisposed to volume depletion or hypovolemia if not closely monitored.
Use in combination with insulin or insulin secretagogues without appropriate dose adjustments.
Use in patients with active bladder cancer under evaluation due to potential concerns related to SGLT2 inhibitors.
Individuals with severe infections or trauma until medical condition stabilizes.
Patients undergoing major surgery where effects on fluid balance may complicate perioperative management.

Drug Interactions

Concomitant use with insulin or insulin secretagogues (e.g., sulfonylureas) increases risk of hypoglycemia; dose adjustments may be necessary.
Rifampin, a potent CYP3A4 inducer, may reduce linagliptin plasma concentrations leading to decreased efficacy.
Diuretics and other antihypertensive agents may enhance dehydration and hypotensive effects due to empagliflozin’s osmotic diuresis.
Drugs that impair renal function can reduce empagliflozin efficacy and increase adverse effect potential.
Coadministration with other antidiabetic agents requires close glycemic monitoring to avoid hypoglycemia or hyperglycemia.
Potential interaction with drugs affecting UGT enzymes that metabolize empagliflozin (e.g., rifampin).
Concomitant use with nephrotoxic drugs could exacerbate renal impairment and decrease Glyxambi safety.
Use with alcohol may increase risk of hypoglycemia and dehydration.
Medications that alter electrolyte balance may interact with empagliflozin’s diuretic effect.
Concomitant use with corticosteroids or sympathomimetic agents may increase blood glucose levels, reducing Glyxambi efficacy.
Use with other glucose-lowering herbal supplements or agents needs caution.
Drugs that delay gastric emptying or affect gastrointestinal motility could theoretically affect absorption.
Caution with drugs that prolong QT interval since hypoglycemia and electrolyte disturbances can exacerbate arrhythmia risk.
No significant interactions noted with renally eliminated or commonly used cardiovascular drugs.
Patient medication regimens should be regularly reviewed for potential new interactions.

Preparations Of The Drug

Glyxambi is available as a fixed-dose combination oral tablet.
Tablet strengths include 10 mg empagliflozin with 5 mg linagliptin, and 25 mg empagliflozin with 5 mg linagliptin.
Supplied in blister packs or bottles with various tablet counts depending on manufacturer and prescription.
Tablets are film-coated and intended for oral administration.
Storage is recommended at controlled room temperature, protected from moisture and heat.
No injectable or alternative formulations of Glyxambi are available as of current approval.
Not formulated for pediatric use; restricted to adult populations only.
Scored tablets may facilitate dose adjustments per physician’s recommendation.
Manufactured under strict quality control to ensure consistent dosing and bioavailability.
Distributed with patient information leaflets detailing usage, precautions, and side effects.
Marketed primarily in countries with regulatory approval including the USA and EU.
Combination drug designed to simplify therapy by reducing pill burden and improving adherence.
Containers include child-resistant caps to prevent accidental ingestion.
Produced by pharmaceutical companies specializing in antidiabetic therapies with established safety profiles.
Compatible with most standard dispensing systems in outpatient and hospital pharmacies.